Citations

Citations to this article as recorded by  

• Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19
  Nancy Xurui Huang, Qi Yuan, Fang Fang, Bryan P. Yan, John E. Sanderson, Masaki Mogi
  PLOS ONE.2023; 18(1): e0280280.     CrossRef
• Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
  Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström
  Journal of the American Heart Association.2022;[Epub]     CrossRef
• Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease
  Rumen Filev, Lionel Rostaing, Mila Lyubomirova, Boris Bogov, Krassimir Kalinov, Dobrin Svinarov
  Medicine.2022; 101(48): e31988.     CrossRef

Citations

Citations to this article as recorded by  

• Sex, racial, ethnic, and geographical disparities in major adverse cardiovascular outcome of glucagon-like peptide-1 receptor agonists among patients with and without diabetes mellitus: A meta-analysis of placebo-controlled randomized controlled trials,
  Frederick Berro Rivera, Nathan Ross B. Bantayan, John Paul Aparece, Linnaeus Louisse A. Cruz, John Vincent Magallong, Polyn Luz Pine, Anne Mira Nicca Idian-Javier, Grace Nooriza O. Lumbang, Edgar V. Lerma, Kyla M. Lara-Breitinger, Martha Gulati, Krishnasw
  Journal of Clinical Lipidology.2024;[Epub]     CrossRef
• Coronary Artery Disease in South Asian Patients: Cardiovascular Risk Factors, Pathogenesis and Treatments
  Vincenzo Sucato, Giuseppe Coppola, Girolamo Manno, Giuseppe Vadalà, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi
  Current Problems in Cardiology.2023; 48(8): 101228.     CrossRef
• Retrospective Analysis of the Effectiveness of Oral Semaglutide in Type 2 Diabetes Mellitus and Its Effect on Cardiometabolic Parameters in Japanese Clinical Settings
  Hodaka Yamada, Masashi Yoshida, Shunsuke Funazaki, Jun Morimoto, Shiori Tonezawa, Asuka Takahashi, Shuichi Nagashima, Kimura Masahiko, Otsuka Kiyoshi, Kazuo Hara
  Journal of Cardiovascular Development and Disease.2023; 10(4): 176.     CrossRef
• Efficacy of treatment with glucagon-like peptide receptor agonists-1 in Asian patients with type 2 diabetes mellitus
  L. Yu. Khamnueva, L. S. Andreeva
  Problems of Endocrinology.2023; 69(2): 38.     CrossRef
• Role of diabetes in stroke: Recent advances in pathophysiology and clinical management
  Sian A. Bradley, Kevin J. Spring, Roy G. Beran, Dimitrios Chatzis, Murray C. Killingsworth, Sonu M. M. Bhaskar
  Diabetes/Metabolism Research and Reviews.2022;[Epub]     CrossRef
• Obesity Pillars Roundtable: Obesity and East Asians
  Harold Edward Bays, Jennifer Ng, Jeffrey Sicat, Michelle Look
  Obesity Pillars.2022; 2: 100011.     CrossRef
• Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
  Calvin Ke, K. M. Venkat Narayan, Juliana C. N. Chan, Prabhat Jha, Baiju R. Shah
  Nature Reviews Endocrinology.2022; 18(7): 413.     CrossRef
• Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
  Timothy M. E. Davis, Anna Giczewska, Yuliya Lokhnygina, Robert J. Mentz, Naveed Sattar, Rury R. Holman
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus
  Xiaoling Cai, Linong Ji
  Diabetes Therapy.2021; 12(7): 1861.     CrossRef
• Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
  Jae-Seung Yun, Seung-Hyun Ko
  Metabolism.2021; 123: 154838.     CrossRef
• Sex and ethnic differences in the cardiovascular complications of type 2 diabetes
  Jian L. Yeo, Emer M. Brady, Gerry P. McCann, Gaurav S. Gulsin
  Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110342.     CrossRef
• Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
  Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Efficacy and safety of dulaglutide in type 2 diabetes patients in endocrinology clinics of Islamabad, Pakistan
  Matiullah Kamin, SajjadAli Khan, UmarYousaf Raja, Osama Ishtiaq, Asmara Malik, Tejhmal Rehman, MuhammadUmar Wahab
  Indian Journal of Endocrinology and Metabolism.2021; 25(5): 456.     CrossRef
• Type 2 Diabetes and Atherosclerotic Cardiovascular Disease in South Asians: a Unique Population with a Growing Challenge
  Afreen I. Shariff, Nitya Kumar, William S. Yancy, Leonor Corsino
  Current Diabetes Reports.2020;[Epub]     CrossRef
• Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
  Christopher S. Wilcox
  Hypertension.2020; 75(4): 894.     CrossRef
• Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
  Liyun He, Na Yang, Lingling Xu, Fan Ping, Wei Li, Yuxiu Li, Huabing Zhang
  Diabetes Therapy.2020; 11(9): 2121.     CrossRef
• 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases
  Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu, Kuan-Cheng Chang, Kou-Gi Shyu, Jin-Long Huang, Cheng-Dao Tsai, Huei-Fong Hung, Ming-En Liu, Tze-Fan Chao,
  Journal of the Chinese Medical Association.2020; 83(7): 587.     CrossRef
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
  Kyung-Soo Kim, Byung-Wan Lee
  Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef

The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.

Citations

Citations to this article as recorded by  

• Anti-inflammatory effect of glucagon-like Peptide-1 receptor agonist on the neurosensory retina in an acute optic nerve injury rat model
  Yeon Woong Chung, Ji Young Lee, Hyun Hee Ju, Jin A. Choi
  European Journal of Pharmacology.2022; 933: 175269.     CrossRef
• Diabetes Risk Data Mining Method Based on Electronic Medical Record Analysis
  Yang Liu, Zhaoxiang Yu, Yunlong Yang, Zhihan Lv
  Journal of Healthcare Engineering.2021; 2021: 1.     CrossRef
• Paradigm Shift for the Treatment of Type 2 Diabetes Mellitus in Patients with Cardiovascular Disease: Cardiologist's Perspective
  Doo Soo Jeon
  Cardiovascular Prevention and Pharmacotherapy.2020; 2(1): 11.     CrossRef
• The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
  Ju-Ming Lu
  Advances in Therapy.2019; 36(4): 798.     CrossRef
• A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
  Irene Romera, Ana Cebrián-Cuenca, Fernando Álvarez-Guisasola, Fernando Gomez-Peralta, Jesús Reviriego
  Diabetes Therapy.2019; 10(1): 5.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
  Hyun Jin Kim
  The Journal of Korean Diabetes.2018; 19(1): 35.     CrossRef

Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic β-cell dysfunction and insulin resistance. Pancreatic β-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve β-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic β-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on β-cell function and β-cell mass in animals and humans.

Citations

Citations to this article as recorded by  

• Harnessing gut cells for functional insulin production: Strategies and challenges
  Kelvin Baafi, John C. March
  Biotechnology Notes.2023; 4: 7.     CrossRef
• Incretin and Pancreatic β-Cell Function in Patients with Type 2 Diabetes
  Chang Ho Ahn, Tae Jung Oh, Se Hee Min, Young Min Cho
  Endocrinology and Metabolism.2023; 38(1): 1.     CrossRef
• Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function
  Simon B. K. Jensen, Christian R. Juhl, Charlotte Janus, Julie R. Lundgren, Christoffer Martinussen, Christoffer Wiingaard, Cecilie Knudsen, Ruth Frikke‐Schmidt, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad, Signe S. Torekov
  Obesity.2023; 31(4): 977.     CrossRef
• How do parasitic worms prevent diabetes? An exploration of their influence on macrophage and β-cell crosstalk
  Inah Camaya, Bronwyn O’Brien, Sheila Donnelly
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review
  Marah Alsayed Hasan, Stanley Schwartz, Victoria McKenna, Richard Ing
  Obesity Surgery.2023; 33(9): 2927.     CrossRef
• Therapeutic Dilemma in Personalized Medicine
  Ehab S. EL Desoky
  Current Reviews in Clinical and Experimental Pharmacology.2022; 17(2): 94.     CrossRef
• Lessons from neonatal β-cell epigenomic for diabetes prevention and treatment
  Amar Abderrahmani, Cécile Jacovetti, Romano Regazzi
  Trends in Endocrinology & Metabolism.2022; 33(6): 378.     CrossRef
• Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
  Neil Tanday, Ryan A. Lafferty, Peter R. Flatt, Nigel Irwin
  Diabetes, Obesity and Metabolism.2022; 24(12): 2353.     CrossRef
• A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes
  Chih-Yuan Wang, Kuo-Chin Huang, Chia-Wen Lu, Chih-Hsun Chu, Chien-Ning Huang, Harn-Shen Chen, I-Te Lee, Jung-Fu Chen, Ching-Chu Chen, Chung-Sen Chen, Chang-Hsun Hsieh, Kai-Jen Tien, Hung-Yu Chien, Yu-Yao Huang, Jui-Pao Hsu, Guang-Tzuu Shane, Ai-Ching Chan
  The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4063.     CrossRef
• Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study
  Tao Tao, Yi Zhang, Yu-Chen Zhu, Jia-Rong Fu, Yu-Ying Wang, Jie Cai, Jing-Yu Ma, Yu Xu, Yi-Ning Gao, Yun Sun, WuQiang Fan, Wei Liu
  The Journal of Clinical Endocrinology & Metabolism.2021; 106(3): e1420.     CrossRef
• The utility of assessing C-peptide in patients with insulin-treated type 2 diabetes: a cross-sectional study
  Tuccinardi Dario, Giorgino Riccardo, Pieralice Silvia, Watanabe Mikiko, Maggi Daria, Palermo Andrea, Defeudis Giuseppe, Fioriti Elvira, Pozzilli Paolo, Manfrini Silvia
  Acta Diabetologica.2021; 58(4): 411.     CrossRef
• Type 2 diabetes: evidence-based medicine approach to glucose-lowering therapy
  E. V. Biryukova, I. A. Morozova, S. V. Rodionova
  Meditsinskiy sovet = Medical Council.2021; (21): 160.     CrossRef
• Emerging Role of Caveolin-1 in GLP-1 Action
  Alessandra Puddu, Davide Maggi
  Frontiers in Endocrinology.2021;[Epub]     CrossRef
• Improvements in HOMA indices and pancreatic endocrinal tissues in type 2-diabetic rats by DPP-4 inhibition and antioxidant potential of an ethanol fruit extract of Withania coagulans
  Heera Ram, Pramod Kumar, Ashok Purohit, Priya Kashyap, Suresh Kumar, Shivani Kumar, Garima Singh, Abdulaziz A. Alqarawi, Abeer Hashem, Elsayed Fathi Abd-Allah, Al-Bandari Fahad Al-Arjani, Bhim Pratap Singh
  Nutrition & Metabolism.2021;[Epub]     CrossRef
• Chop / Ddit3 depletion in β cells alleviates ER stress and corrects hepatic steatosis in mice
  Jing Yong, Vishal S. Parekh, Shannon M. Reilly, Jonamani Nayak, Zhouji Chen, Cynthia Lebeaupin, Insook Jang, Jiangwei Zhang, Thazha P. Prakash, Hong Sun, Sue Murray, Shuling Guo, Julio E. Ayala, Leslie S. Satin, Alan R. Saltiel, Randal J. Kaufman
  Science Translational Medicine.2021;[Epub]     CrossRef
• Assessment of Insulin Secretion and Insulin Resistance in Human
  So Young Park, Jean-François Gautier, Suk Chon
  Diabetes & Metabolism Journal.2021; 45(5): 641.     CrossRef
• Targeted pharmacological therapy restores β-cell function for diabetes remission
  Stephan Sachs, Aimée Bastidas-Ponce, Sophie Tritschler, Mostafa Bakhti, Anika Böttcher, Miguel A. Sánchez-Garrido, Marta Tarquis-Medina, Maximilian Kleinert, Katrin Fischer, Sigrid Jall, Alexandra Harger, Erik Bader, Sara Roscioni, Siegfried Ussar, Annett
  Nature Metabolism.2020; 2(2): 192.     CrossRef
• The Relationship Between Timing of Initiation on a Glucagon-like Peptide-1 Receptor Agonist and Glycosylated Hemoglobin Values Among Patients With Type 2 Diabetes
  Kristina S. Boye, Reema Mody, Maureen J. Lage, Raleigh E. Malik
  Clinical Therapeutics.2020; 42(9): 1812.     CrossRef
• Short-term renal and metabolic effects of low dose vildagliptin treatment added-on insulin therapy in non-proteinuric patients with type 2 diabetes: open-label randomized prospective study
  Valentina K. Bayrasheva, Ivan Y. Pchelin, Vladimir A. Dobronravov, Alina Yu. Babenko, Svetlana G. Chefu, Ivan S. Shatalov, Volha N. Vasilkova, Natalia V. Hudiakova, Alexandra N. Ivanova, Pavel A. Andoskin, Elena N. Grineva
  Archives of Endocrinology and Metabolism.2020;[Epub]     CrossRef
• A Phenotypic Screen Identifies Calcium Overload as a Key Mechanism of β-Cell Glucolipotoxicity
  Jennifer Vogel, Jianning Yin, Liansheng Su, Sharon X. Wang, Richard Zessis, Sena Fowler, Chun-Hao Chiu, Aaron C. Wilson, Amy Chen, Frederic Zecri, Gordon Turner, Thomas M. Smith, Brian DeChristopher, Heming Xing, Deborah M. Rothman, Xinming Cai, Alina Ber
  Diabetes.2020; 69(5): 1032.     CrossRef
• Neuropeptide 26RFa (QRFP) is a key regulator of glucose homeostasis and its activity is markedly altered in obese/hyperglycemic mice
  Gaëtan Prévost, Arnaud Arabo, Marie-Anne Le Solliec, Justine Bons, Marie Picot, Julie Maucotel, Hind Berrahmoune, Mouna El Mehdi, Saloua Cherifi, Alexandre Benani, Emmanuelle Nédélec, Moïse Coëffier, Jérôme Leprince, Anneli Nordqvist, Valéry Brunel, Pierr
  American Journal of Physiology-Endocrinology and Metabolism.2019; 317(1): E147.     CrossRef
• Gastrin analogue administration adds no significant glycaemic benefit to a glucagon‐like peptide‐1 receptor agonist acutely or after washout of both analogues
  Krister Bokvist, Ying Ding, William H. Landschulz, Vikram Sinha, Aleksandra Pastrak, Ruth M. Belin
  Diabetes, Obesity and Metabolism.2019; 21(7): 1606.     CrossRef
• Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1
  Lie-Chwen Lin, Lin-Chien Lee, Cheng Huang, Chiung-Tong Chen, Jen-Shin Song, Young-Ji Shiao, Hui-Kang Liu
  Phytomedicine.2019; 62: 152946.     CrossRef
• The future of new drugs for diabetes management
  Clifford J. Bailey, Caroline Day
  Diabetes Research and Clinical Practice.2019; 155: 107785.     CrossRef
• Compact fluidic system for functional assessment of pancreatic islets
  Takeshi Hori, Kei Yamane, Takayuki Anazawa, Osamu Kurosawa, Hiroo Iwata
  Biomedical Microdevices.2019;[Epub]     CrossRef
• Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
  Yazhou Li, Kelli L. Vaughan, David Tweedie, Jin Jung, Hee Kyung Kim, Ho-Il Choi, Dong Seok Kim, Julie A. Mattison, Nigel H. Greig
  Scientific Reports.2019;[Epub]     CrossRef
• Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury
  Miaad Bader, Yazhou Li, Daniela Lecca, Vardit Rubovitch, David Tweedie, Elliot Glotfelty, Lital Rachmany, Hee Kyung Kim, Ho-Il Choi, Barry J. Hoffer, Chaim G. Pick, Nigel H. Greig, Dong Seok Kim
  Neurobiology of Disease.2019; 124: 439.     CrossRef
• Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential
  N.M. Pathak, V. Pathak, V.A. Gault, S. McClean, N. Irwin, P.R. Flatt
  Biochemical Pharmacology.2018; 155: 264.     CrossRef
• Human EndoC-βH1 β-cells form pseudoislets with improved glucose sensitivity and enhanced GLP-1 signaling in the presence of islet-derived endothelial cells
  Michael G. Spelios, Lauren A. Afinowicz, Regine C. Tipon, Eitan M. Akirav
  American Journal of Physiology-Endocrinology and Metabolism.2018; 314(5): E512.     CrossRef
• Vildagliptin: ten years in the service for type 2 diabetes mellitus patients. The journey of discovery, innovation and success in clinical practice
  Tatiana Yu. Demidova
  Problems of Endocrinology.2018; 64(5): 336.     CrossRef
• Thromboxane-Dependent Platelet Activation in Obese Subjects with Prediabetes or Early Type 2 Diabetes: Effects of Liraglutide- or Lifestyle Changes-Induced Weight Loss
  Paola Simeone, Rossella Liani, Romina Tripaldi, Augusto Di Castelnuovo, Maria Guagnano, Armando Tartaro, Riccardo Bonadonna, Virginia Federico, Francesco Cipollone, Agostino Consoli, Francesca Santilli
  Nutrients.2018; 10(12): 1872.     CrossRef
• Nutrient regulation of β-cell function: what do islet cell/animal studies tell us?
  R Carlessi, K N Keane, C Mamotte, P Newsholme
  European Journal of Clinical Nutrition.2017; 71(7): 890.     CrossRef
• Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice
  You-Cheol Hwang, Ari Kim, Euna Jo, Yeoree Yang, Jae-Hyoung Cho, Byung-Wan Lee
  BMC Endocrine Disorders.2017;[Epub]     CrossRef
• Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
  Sang‐Mo Hong, Cheol‐Young Park, Dong‐Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun‐Ho Yoon, Ji‐Oh Mok, Kyong Soo Park, Sung‐Woo Park
  Diabetes, Obesity and Metabolism.2017; 19(5): 654.     CrossRef
• The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)
  Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Tatsuya Atsumi
  Cardiovascular Diabetology.2017;[Epub]     CrossRef
• Recent Advances in Effect‐directed Enzyme Assays based on Thin‐layer Chromatography
  Sarah Bräm, Evelyn Wolfram
  Phytochemical Analysis.2017; 28(2): 74.     CrossRef
• Efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24‐week, multicentre, randomized, double‐blind, placebo‐
  Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang‐Wook Kim, Jeong Hyun Park, Kwa
  Diabetes, Obesity and Metabolism.2017; 19(5): 635.     CrossRef
• Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
• DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control
  Eun Ju Bae
  Archives of Pharmacal Research.2016; 39(8): 1114.     CrossRef
• Liraglutide Enhances the Efficacy of Human Mesenchymal Stem Cells in Preserving Islet ß-cell Function in Severe Non-obese Diabetic Mice
  Li-rong Li, Jing Lu, Xiao-lei Jia, Hui Hui, Jie Zhang, Ying Liu, Wei-juan Cui, Qian-yue Xu, Da-long Zhu
  Molecular Medicine.2016; 22(1): 800.     CrossRef

Obesity associated with unhealthy diet and lack of exercise is shown to contribute to the onset and/or aggravation of the metabolic syndrome and diabetes, thus placing affected individuals at increased risk of cardiovascular disease and cancer. Plasma adiponectin levels are decreased in obesity, which causes insulin resistance and diabetes. Therefore, we identified adiponectin receptors (AdipoRs) as the therapeutic target. It was suggested that, similarly to caloric restriction and exercise, activation of the AdipoRs may have the potential not only to improve lifestyle-related diseases but to contribute to prolonged the shortened lifespan on a high caloric unhealthy diet. To this end, we have identified "AdipoRon" as an adiponectin receptor agonist. Indeed, AdipoRon ameliorated diabetes associated with obesity as well as to increase exercise endurance, thus prolonging shortened lifespan of obese mice fed on a high fat diet. Additionally, we have recently determined the crystal structures of the human AdipoRs. The seven-transmembrane helices of AdipoRs are structurally distinct from those of G-protein coupled receptors. It is expected that these findings will contribute not only to the elucidation of the AdipoR-related signal transduction but to the development and optimization of AdipoR-targeted therapeutics for obesity-related diseases such as diabetes.

Citations

Citations to this article as recorded by  

• Identification of a novel adiponectin receptor and opioid receptor dual acting agonist as a potential treatment for diabetic neuropathy
  Oscar Ka-Fai Ma, Simone Ronsisvalle, Livia Basile, Ariya Weiman Xiang, Cristina Tomasella, Federica Sipala, Matteo Pappalardo, Koon-Ho Chan, Danilo Milardi, Roy Chun-Laam Ng, Salvatore Guccione
  Biomedicine & Pharmacotherapy.2023; 158: 114141.     CrossRef
• AdipoRon Effect on Expression of Lipid Metabolism Genes in Cultured Human Primary Macrophages
  I. A. Pobozheva, K. V. Dracheva, S. N. Pchelina, V. V. Miroshnikova
  Molecular Biology.2023; 57(4): 616.     CrossRef
• The Antiviral Potential of AdipoRon, an Adiponectin Receptor Agonist, Reveals the Ability of Zika Virus to Deregulate Adiponectin Receptor Expression
  Daed El Safadi, Grégorie Lebeau, Jonathan Turpin, Christian Lefebvre d’Hellencourt, Nicolas Diotel, Wildriss Viranaicken, Pascale Krejbich-Trotot
  Viruses.2023; 16(1): 24.     CrossRef
• The Effect of Adiporon on Lipid Metabolism Genes Expression in Human Macrophages
  I. A. Pobozheva, K. V. Dracheva, S. N. Pchelina, V. V. Miroshnikova
  Молекулярная биология.2023; 57(4): 623.     CrossRef
• The effects of high intensity-interval training on vaspin, adiponectin and leptin levels in women with polycystic ovary syndrome
  H. Ş. Aktaş, Y. E. Uzun, O. Kutlu, H. H. Pençe, F. Özçelik, E. Ö. Çil, L. Irak, Ö. Altun, M. Özcan, N. Özsoy, Ş. Aydın Yoldemir, S. Kalyon, Y. Arman, T. Tükek
  Archives of Physiology and Biochemistry.2022; 128(1): 37.     CrossRef
• G protein-coupled receptors that influence lifespan of human and animal models
  Francisco Alejandro Lagunas-Rangel
  Biogerontology.2022; 23(1): 1.     CrossRef
• Protective effects of AdipoRon on the liver of Huoyan goose fed a high-fat diet
  Zhongzan Cao, Ben Ma, Chengyu Cui, Jiahui Zhao, Sidi Liu, Yunqiao Qiu, Yan Zheng, Ming Gao, Xinhong Luan
  Poultry Science.2022; 101(4): 101708.     CrossRef
• AdipoRon exerts opposing effects on insulin sensitivity via fibroblast growth factor 21–mediated time-dependent mechanisms
  Yongliang Wang, Huan Liu, Ruixin Zhang, Yuyao Xiang, Junfeng Lu, Bo Xia, Liang Peng, Jiangwei Wu
  Journal of Biological Chemistry.2022; 298(3): 101641.     CrossRef
• Compendious Review on Adipokines of Corpulence
  Feryal Hashim
  Research Journal of Pharmacy and Technology.2022; : 4315.     CrossRef
• AdipoR agonist increases insulin sensitivity and exercise endurance in AdipoR-humanized mice
  Masato Iwabu, Miki Okada-Iwabu, Hiroaki Tanabe, Nozomi Ohuchi, Keiko Miyata, Toshiko Kobori, Sara Odawara, Yuri Kadowaki, Shigeyuki Yokoyama, Toshimasa Yamauchi, Takashi Kadowaki
  Communications Biology.2021;[Epub]     CrossRef
• ADIPOR1 regulates genes involved in milk fat metabolism in goat mammary epithelial cells
  Wangsheng Zhao, Michael Adjei, Hongmei Wang, Yueling Yangliu, Jiangjiang Zhu, Huijuan Wu
  Research in Veterinary Science.2021; 137: 194.     CrossRef
• Differentiation of THP-1 monocytes to macrophages increased mitochondrial DNA copy number but did not increase expression of mitochondrial respiratory proteins or mitochondrial transcription factor A
  Mizuho Okamoto, Masanori Shimogishi, Akari Nakamura, Yusuke Suga, Kyosuke Sugawara, Michio Sato, Ryotaro Nishi, Akio Fujisawa, Yorihiro Yamamoto, Misato Kashiba
  Archives of Biochemistry and Biophysics.2021; 710: 108988.     CrossRef
• Clinical features, treatment and rehabilitation of new coronavirus infection in patients with metabolic syndrome
  Dmitry O. Ivanov, Yury P. Uspenskiy, Andrey M. Sarana, Yulia A. Fominykh, Iana V. Sousova, Dmitry V. Zakharov
  Pediatrician (St. Petersburg).2021; 12(5): 5.     CrossRef
• AdipoRon promotes diabetic fracture repair through endochondral ossification-based bone repair by enhancing survival and differentiation of chondrocytes
  Zhongyi Wang, Jinxin Tang, Ying Li, Yu Wang, Yanyang Guo, Qisheng Tu, Jake Chen, Chen Wang
  Experimental Cell Research.2020; 387(2): 111757.     CrossRef
• Discovery of AdipoRon analogues as novel AMPK activators without inhibiting mitochondrial complex I
  Geng Sun, Yanping You, Haobin Li, Yalong Cheng, Ming Qian, Xinyu Zhou, Haoliang Yuan, Qing-Long Xu, Liang Dai, Pengfei Wang, Keguang Cheng, Xiaoan Wen, Caiping Chen
  European Journal of Medicinal Chemistry.2020; 200: 112466.     CrossRef
• Insights Into the Controversial Aspects of Adiponectin in Cardiometabolic Disorders
  Emilio Antonio Francischetti, Rômulo Sperduto Dezonne, Cláudia Maria Pereira, Cyro José de Moraes Martins, Bruno Miguel Jorge Celoria, Patrícia Aguiar Cardoso de Oliveira, Virgínia Genelhu de Abreu
  Hormone and Metabolic Research.2020; 52(10): 695.     CrossRef
• Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together?
  Michel Abou-Samra, Camille M. Selvais, Nicolas Dubuisson, Sonia M. Brichard
  International Journal of Molecular Sciences.2020; 21(7): 2620.     CrossRef
• AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
  Michel Abou‐Samra, Camille M. Selvais, Raphael Boursereau, Sophie Lecompte, Laurence Noel, Sonia M. Brichard
  Journal of Cachexia, Sarcopenia and Muscle.2020; 11(2): 518.     CrossRef
• Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease
  Rim Rafeh, Anissa Viveiros, Gavin Y. Oudit, Ahmed F. El-Yazbi
  Clinical Science.2020; 134(7): 827.     CrossRef
• Therapeutic effects of AdipoRon on liver inflammation and fibrosis induced by CCl4 in mice
  Min Sha, Yaru Gao, Can Deng, Yuemeng Wan, Yuan Zhuang, Xiaochuan Hu, Ying Wang
  International Immunopharmacology.2020; 79: 106157.     CrossRef
• AdipoRon: A Novel Insulin Sensitizer in Various Complications and the Underlying Mechanisms: A Review
  Ishfaq Ahmad Bhat, Shaheen Wasil Kabeer, Mohammad Irshad Reza, Reyaz Hassan Mir, Muhammad Ovais Dar
  Current Molecular Pharmacology.2020; 13(2): 94.     CrossRef
• Case Report: Concurrent Resistance and Aerobic Training Regulate Adiponectin Expression and Disease Severity in Multiple Sclerosis: A Case Study
  Elisa Grazioli, Ersilia Nigro, Claudia Cerulli, Giovanna Borriello, Annamaria Mancini, Eliana Tranchita, Rita Polito, Attilio Parisi, Pasqualina Buono, Aurora Daniele
  Frontiers in Neuroscience.2020;[Epub]     CrossRef
• Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease
  Yaeni Kim, Cheol Whee Park
  International Journal of Molecular Sciences.2019; 20(7): 1782.     CrossRef
• Drug development research for novel adiponectin receptor-targeted antidiabetic drugs contributing to healthy longevity
  Miki Okada-Iwabu, Masato Iwabu, Toshimasa Yamauchi, Takashi Kadowaki
  Diabetology International.2019; 10(4): 237.     CrossRef
• Potential Role of Adiponectin Receptor Agonist, AdipoRon in Cardiometabolic Disease
  Eunhee Cho, Sewon Lee
  Exercise Science.2019; 28(2): 102.     CrossRef
• Adiponectin for the treatment of diabetic nephropathy
  Jun Young Lee, Jae Won Yang, Byoung Geun Han, Seung Ok Choi, Jae Seok Kim
  The Korean Journal of Internal Medicine.2019; 34(3): 480.     CrossRef
• Adiponectin receptor agonist AdipoRon relieves endotoxin-induced acute hepatitis in mice
  Wen-Ze Xiao, Li Zhang
  Chinese Medical Journal.2019; 132(20): 2438.     CrossRef
• Adiponectin/AdipoR Research and Its Implications for Lifestyle-Related Diseases
  Masato Iwabu, Miki Okada-Iwabu, Toshimasa Yamauchi, Takashi Kadowaki
  Frontiers in Cardiovascular Medicine.2019;[Epub]     CrossRef
• Examining the Potential of Developing and Implementing Use of Adiponectin-Targeted Therapeutics for Metabolic and Cardiovascular Diseases
  Ying Liu, Vivian Vu, Gary Sweeney
  Frontiers in Endocrinology.2019;[Epub]     CrossRef
• The role of immune cells in the development of adipose tissue dysfunction in cardiovascular diseases
  E. G. Uchasova, O. V. Gruzdeva, Yu. A. Dyleva, E. V. Belik, O. L. Barbarash
  Russian Journal of Cardiology.2019; (4): 92.     CrossRef
• Adiponectin and Inflammation in Health and Disease: An Update
  Alice G. Geagea, Samir Mallat, Charbel F. Matar, Raymond Zerbe, Estelle Filfili, Maria Francis, Hanine Haidar, Abdo Jurjus
  Open Medicine Journal.2018; 5(1): 20.     CrossRef
• Structure and function analysis of adiponectin receptors toward development of novel antidiabetic agents promoting healthy longevity
  Miki Okada-Iwabu, Masato Iwabu, Toshimasa Yamauchi, Takashi Kadowaki
  Endocrine Journal.2018; 65(10): 971.     CrossRef
• Adiponectin induced AMP-activated protein kinase impairment mediates insulin resistance in Bama mini-pig fed high-fat and high-sucrose diet
  Miaomiao Niu, Lei Xiang, Yaqian Liu, Yuqiong Zhao, Jifang Yuan, Xin Dai, Hua Chen
  Asian-Australasian Journal of Animal Sciences.2017; 30(8): 1190.     CrossRef
• The role of adiponectin receptors in the regulation of synaptic transmission in the hippocampus
  Filippo Weisz, Sonia Piccinin, Dalila Mango, Richard Teke Ngomba, Nicola B. Mercuri, Ferdinando Nicoletti, Robert Nisticò
  Synapse.2017;[Epub]     CrossRef
• Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease
  Lavinia Woodward, Ioannis Akoumianakis, Charalambos Antoniades
  British Journal of Pharmacology.2017; 174(22): 4007.     CrossRef
• Annual banned‐substance review: analytical approaches in human sports drug testing
  Mario Thevis, Tiia Kuuranne, Hans Geyer, Wilhelm Schänzer
  Drug Testing and Analysis.2017; 9(1): 6.     CrossRef
• Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets
  Yadan Chen, Haiming Ma, Dasheng Zhu, Guowei Zhao, Lili Wang, Xiujuan Fu, Wei Chen
  PPAR Research.2017; 2017: 1.     CrossRef
• Adiponectin and Its Receptors in Diabetic Kidney Disease: Molecular Mechanisms and Clinical Potential
  Dongqing Zha, Xiaoyan Wu, Ping Gao
  Endocrinology.2017; 158(7): 2022.     CrossRef
• Role of pro- and anti-inflammatory phenomena in the physiopathology of type 2 diabetes and obesity
  Luciano Pirola, José Candido Ferraz
  World Journal of Biological Chemistry.2017; 8(2): 120.     CrossRef
• Perivascular adipose tissue as a regulator of vascular disease pathogenesis: identifying novel therapeutic targets
  Ioannis Akoumianakis, Akansha Tarun, Charalambos Antoniades
  British Journal of Pharmacology.2017; 174(20): 3411.     CrossRef
• Insight into the Dissociation of Behavior from Histology in Synucleinopathies and in Related Neurodegenerative Diseases
  Kazunari Sekiyama, Yoshiki Takamatsu, Wakako Koike, Masaaki Waragai, Takato Takenouchi, Shuei Sugama, Makoto Hashimoto
  Journal of Alzheimer's Disease.2016; 52(3): 831.     CrossRef
• Castration induced browning in subcutaneous white adipose tissue in male mice
  Osamu Hashimoto, Tatsuya Noda, Atsushi Morita, Masahiro Morita, Hirofumi Ohtsuki, Makoto Sugiyama, Masayuki Funaba
  Biochemical and Biophysical Research Communications.2016; 478(4): 1746.     CrossRef
• Aldosterone Production and Signaling Dysregulation in Obesity
  Andrea Vecchiola, Carlos F. Lagos, Cristian A. Carvajal, Rene Baudrand, Carlos E. Fardella
  Current Hypertension Reports.2016;[Epub]     CrossRef

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce glycosylated hemoglobin (HbA1c, 0.5% to 1.0%), and are associated with moderate weight loss and a relatively low risk of hypoglycemia. There are differences between Asian and non-Asian populations. We reviewed available data on GLP-1RAs, focusing on Korean patients, to better understand their risk/benefit profile and help inform local clinical practice. Control of postprandial hyperglycemia is important in Asians in whom the prevalence of post-challenge hyperglycemia is higher (vs. non-Asians). The weight lowering effects of GLP-1RAs are becoming more salient as the prevalence of overweight and obesity among Korean patients increases. The higher rate of gastrointestinal adverse events amongst Asian patients in clinical trials may be caused by higher drug exposure due to the lower body mass index of the participants (vs. non-Asian studies). Data on the durability of weight loss, clinically important health outcomes, safety and optimal dosing in Korean patients are lacking. Use of GLP-1RAs is appropriate in several patient groups, including patients whose HbA1c is uncontrolled, especially if this is due to postprandial glucose excursions and patients who are overweight or obese due to dietary problems (e.g., appetite control). The potential for gastrointestinal adverse events should be explained to patients at treatment initiation to facilitate the promotion of better compliance.

Citations

Citations to this article as recorded by  

• Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy
  Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
  Frontiers in Endocrinology.2022;[Epub]     CrossRef
• Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
• Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
  Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
  The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef

Although glucose-lowering treatment shows some risk lowering effects in cardiovascular diseases, risks of macrovascular and microvascular complications have still remained, and development of new therapeutic strategies is needed. Recent data have shown that peroxisome proliferator activated receptor-α (PPAR-α) plays a pivotal role in the regulation of lipid homeostasis, fatty acid oxidation, cellular differentiation, and immune response such as inflammation or vascularization related to diabetic complication. This review will re-examine the metabolic role of PPAR-α, summarize data from clinical studies on the effect of PPAR-α agonist in diabetes, and will discuss the possible therapeutic role of PPAR-α activation.

Citations

Citations to this article as recorded by  

• Recent Insights into the Etiopathogenesis of Diabetic Retinopathy and Its Management
  Arpon Biswas, Abhijit Deb Choudhury, Sristi Agrawal, Amol Chhatrapati Bisen, Sachin Nashik Sanap, Sarvesh Kumar Verma, Mukesh Kumar, Anjali Mishra, Shivansh Kumar, Mridula Chauhan, Rabi Sankar Bhatta
  Journal of Ocular Pharmacology and Therapeutics.2024; 40(1): 13.     CrossRef
• Counteracting health risks by Modulating Homeostatic Signaling
  Junqiang J. Tian, Mark Levy, Xuekai Zhang, Robert Sinnott, Rolando Maddela
  Pharmacological Research.2022; 182: 106281.     CrossRef
• Moringa oleifera leaf extract influences oxidative metabolism in C2C12 myotubes through SIRT1-PPARα pathway
  Guglielmo Duranti, Mariateresa Maldini, Domenico Crognale, Stefania Sabatini, Federica Corana, Katy Horner, Roberta Ceci
  Phytomedicine Plus.2021; 1(1): 100014.     CrossRef
• Diabetes risk associated with plasma epoxylipid levels
  John D. Imig
  eBioMedicine.2021; 66: 103331.     CrossRef
• Genome-Wide Characterization of Alternative Splicing Events and Their Responses to Cold Stress in Tilapia
  Bi Jun Li, Zong Xian Zhu, Hui Qin, Zi Ning Meng, Hao Ran Lin, Jun Hong Xia
  Frontiers in Genetics.2020;[Epub]     CrossRef
• PPARγ provides anti-inflammatory and protective effects in intrahepatic cholestasis of pregnancy through NF-κB pathway
  Yan Zhang, Xiaoping Huang, Jie Zhou, Yongxiang Yin, Ting Zhang, Daozhen Chen
  Biochemical and Biophysical Research Communications.2018; 504(4): 834.     CrossRef
• Fermented Ginseng Contains an Agonist of Peroxisome Proliferator Activated Receptors α and γ
  Kentaro Igami, Yosuke Shimojo, Hisatomi Ito, Toshitsugu Miyazaki, Fusako Nakano, Yoshiki Kashiwada
  Journal of Medicinal Food.2016; 19(9): 817.     CrossRef
• Long-term oral administration of osteocalcin induces insulin resistance in male mice fed a high-fat, high-sucrose diet
  Yu Yasutake, Akiko Mizokami, Tomoyo Kawakubo-Yasukochi, Sakura Chishaki, Ichiro Takahashi, Hiroshi Takeuchi, Masato Hirata
  American Journal of Physiology-Endocrinology and Metabolism.2016; 310(8): E662.     CrossRef
• Peroxisome Proliferator-Activated Receptor-γGene Expression and Its Association with Oxidative Stress in Patients with Metabolic Syndrome
  Mehdi Hatami, Massoud Saidijam, Reza Yadegarzari, Shiva Borzuei, Alireza Soltanian, Marzieh Safi Arian, Mohammad Taghi Goodarzi
  Chonnam Medical Journal.2016; 52(3): 201.     CrossRef
• Short Exposure to a High-Sucrose Diet and the First ‘Hit' of Nonalcoholic Fatty Liver Disease in Mice
  Flavia Fernandes-Lima, Thiago Luís Ribeiro Gomes Monte, Fernanda Amorim de Morais Nascimento, Bianca Martins Gregório
  Cells Tissues Organs.2016; 201(6): 464.     CrossRef
• In vitro evaluation of dual agonists for PPARγ/β from the flower of Edgeworthia gardneri (wall.) Meisn
  Die Gao, Yong-lan Zhang, Pan Xu, Ye-xin Lin, Feng-qing Yang, Jian-hui Liu, Hai-wen Zhu, Zhi-ning Xia
  Journal of Ethnopharmacology.2015; 162: 14.     CrossRef
• PPARα Agonist Fenofibrate Ameliorates Learning and Memory Deficits in Rats Following Global Cerebral Ischemia
  Ai-Guo Xuan, Yan Chen, Da-Hong Long, Meng Zhang, Wei-Dong Ji, Wen-Juan Zhang, Ji-Hong Liu, Le-Peng Hong, Xiao-Song He, Wen-Liang Chen
  Molecular Neurobiology.2015; 52(1): 601.     CrossRef
• Modulation of Cardiac Connexin-43 by Omega-3 Fatty Acid Ethyl-Ester Supplementation Demonstrated in Spontaneously Diabetic Rats
  J. RADOSINSKA, L. H. KURAHARA, K. HIRAISHI, C. VICZENCZOVA, T. EGAN BENOVA, B. SZEIFFOVA BACOVA, V. DOSENKO, J. NAVAROVA, B. OBSITNIK, I. IMANAGA, T. SOUKUP, N. TRIBULOVA
  Physiological Research.2015; : 795.     CrossRef
• Does Bosentan Protect Diabetic Brain Alterations in Rats? The Role of Endothelin‐1 in the Diabetic Brain
  Recep Demir, Elif Cadirci, Erol Akpinar, Yasemin Cayir, Hasan Tarik Atmaca, Harun Un, Celalettin Semih Kunak, Muhammed Yayla, Zafer Bayraktutan, Ilknur Demir
  Basic & Clinical Pharmacology & Toxicology.2015; 116(3): 236.     CrossRef
• The effect of pioglitazone on aldosterone and cortisol production in HAC15 human adrenocortical carcinoma cells
  Zhi-qiang Pan, Ding Xie, Vivek Choudhary, Mutsa Seremwe, Ying-Ying Tsai, Lawrence Olala, Xunsheng Chen, Wendy B. Bollag
  Molecular and Cellular Endocrinology.2014; 394(1-2): 119.     CrossRef
• Icariin Is A PPARα Activator Inducing Lipid Metabolic Gene Expression in Mice
  Yuan-Fu Lu, Yun-Yan Xu, Feng Jin, Qin Wu, Jing-Shan Shi, Jie Liu
  Molecules.2014; 19(11): 18179.     CrossRef
• Canola Oil Influence on Azoxymethane-induced Colon Carcinogenesis, Hypertriglyceridemia and Hyperglycemia in Kunming Mice
  Xiao-Qiong He, Simon Angelo Cichello, Jia-Li Duan, Jin Zhou
  Asian Pacific Journal of Cancer Prevention.2014; 15(6): 2477.     CrossRef
• Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus
  Emily Weidman-Evans, Steven M Metz, Jeffery D Evans
  Expert Review of Clinical Pharmacology.2014; 7(2): 225.     CrossRef
• Enhanced pan‐peroxisome proliferator‐activated receptor gene and protein expression in adipose tissue of diet‐induced obese mice treated with telmisartan
  Aline Penna‐de‐Carvalho, Francielle Graus‐Nunes, Júlia Rabelo‐Andrade, Carlos Alberto Mandarim‐de‐Lacerda, Vanessa Souza‐Mello
  Experimental Physiology.2014; 99(12): 1663.     CrossRef

Citations

Citations to this article as recorded by  

• Beneficial effect of Combination with Korean Red Ginseng and Morus alba in metabolic syndrome
  Yun Jung Lee, Hye Yoom Kim, Jung Joo Yoon, So Min Lee, You Mee Ahn, Joung Hyun Kho, Min Chul Kho, Ho Sub Lee, Kyung Min Choi, Dae Gill Kang
  The Korea Journal of Herbology.2012; 27(6): 99.     CrossRef
• Effects of Mixed Extract from Lycium chinense, Cordyceps militaris, and Acanthopanax senticosus on Glucose-Regulating Enzymes of HepG2 in Hyperglycemic Conditions
  Dae-Jung Kim, Jeong-Mi Kim, Tae-Hyuk Kim, Jong-Mi Baek, Hyun-Sook Kim, Myeon Choe
  Journal of the Korean Society of Food Science and Nutrition.2010; 39(9): 1257.     CrossRef